← Insider Monitor
Beam Therapeutics Inc. logo
BEAM

Beam Therapeutics Inc.

Nasdaq · Biological Products, (No Diagnostic Substances)

2
Insider trades
0
Congress trades

Company Overview

A concise company profile alongside the latest public filing activity.

Beam Therapeutics is a biotechnology company developing precision genetic medicines using base editing, a technology that makes single-letter changes to DNA to correct disease-causing mutations without cutting the DNA strand. Its pipeline targets diseases including sickle cell disease, alpha-1 antitrypsin deficiency, and other genetic and immune-related conditions.

Industry
Biological Products, (No Diagnostic Substances)
Headquarters
Cambridge, MA
Exchange
Nasdaq

Company profile sourced from SEC filings.

Corporate Insider Trades

Open-market purchases and sales by directors, officers, and other company insiders.

InsiderTypeValueDate
Evans John M.CEOSell$600KOct 16, 2026
Evans John M.CEOSell$589KOct 15, 2026

Source: SEC EDGAR Form 4 filings

Congressional Trades

Recent disclosures by members of the U.S. House and Senate.

No recent congressional disclosures found for BEAM.

Source: Senate eFD and House Clerk STOCK Act disclosures

Get notable BEAM activity by email

Free alerts for the insider and congressional trades worth watching.

SMS is optional: we only save your number if you check the consent box and provide a valid number. US mobile numbers only.

SMS Terms and Privacy Policy.

By submitting your email address, you will receive a free subscription to the MySmarTrend e-letter, and offers from us and our affiliates that we think might interest you. You can unsubscribe at any time. Privacy Policy.

For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.